Herbst Highlights Link Between Biomarkers and Improved OS With Atezolizumab in NSCLC

Jessica Hergert
Published: Thursday, Jan 09, 2020
Roy Herbst, MD, PhD, chief of Medical Oncology, professor of Medicine, Yale Cancer Center, Smilow Cancer Hospital

Roy Herbst, MD, PhD

Initial findings from the phase III IMpower110 study showed that frontline atezolizumab (Tecentriq) extended overall survival (OS) compared with platinum-based chemotherapy in patients with advanced non–small cell lung cancer (NSCLC) who have high PD-L1 expression, said Roy S. Herbst, MD, PhD.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication